What is BMRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BMRA?

P/E (TTM) is n/a and 52-week range is $1.45 to $3.21 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BMRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BMRA?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-376M, EPS (TTM) near $-1.26 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Biomerica Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Irvine, California, US, 3.1M shares outstanding, ISIN US09061H4065 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Biomerica Inc

$BMRA

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$1.85

+0.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. The firm develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.

Employees

Website

biomerica.com/

IPO

1980-03-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)